Caspofungin acetate
INDICATIONS
FDA
FDA
- Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other anti-fungal therapy.
- Candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections.
- Note: not well studied in endocarditis, osteomyelitis, and meningitis (low CNS penetration) due to Candida.
- Esophageal candidiasis (authors’ opinion: would reserve caspofungin for azole-resistant cases).
- Empiric treatment of presumed fungal infections in febrile neutropenic patients.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: May 1, 2017
Citation
Pham, Paul A, and John G Bartlett. "Caspofungin Acetate." Johns Hopkins ABX Guide, The Johns Hopkins University, 2017. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540083/all/Caspofungin_acetate.
Pham PA, Bartlett JG. Caspofungin acetate. Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540083/all/Caspofungin_acetate. Accessed October 11, 2024.
Pham, P. A., & Bartlett, J. G. (2017). Caspofungin acetate. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540083/all/Caspofungin_acetate
Pham PA, Bartlett JG. Caspofungin Acetate [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. [cited 2024 October 11]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540083/all/Caspofungin_acetate.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Caspofungin acetate
ID - 540083
A1 - Pham,Paul,Pharm.D.
AU - Bartlett,John,M.D.
Y1 - 2017/05/01/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540083/all/Caspofungin_acetate
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -